Organovo has patented a method to assess renal toxicity of therapeutic agents using a three-dimensional, engineered, bioprinted, biological renal tubule model. The model consists of renal interstitial tissue and renal epithelial tissue, allowing for measurement of viability and functionality of renal tubular epithelial cells. GlobalData’s report on Organovo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Organovo, 3D Bioprinting was a key innovation area identified from patents. Organovo's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Bioprinted renal tissue for assessing renal toxicity of therapeutic agents
A recently granted patent (Publication Number: US11867689B2) outlines a method for assessing the renal toxicity of therapeutic agents using a three-dimensional, engineered, bioprinted, biological renal tubule model. The method involves contacting the therapeutic agent with the model, which consists of layers of renal interstitial tissue and renal epithelial tissue containing specific cell types. By measuring the viability or functionality of the renal tubular epithelial cells post-contact, the method allows for the assessment of renal toxicity based on these measurements.
Furthermore, the patent details additional methods for testing the viability of renal tubular epithelial cells and the effect of therapeutic agents on renal transport molecules using similar bioprinted renal tubule models. These methods involve measuring gamma glutamyl-transferase (GGT) activity and transport molecule activity in the model, respectively. The patent specifies the inclusion of cells from subjects with specific kidney diseases in the model, such as polycystic kidney disease, diabetes mellitus type II, or renal cell carcinoma, to provide a more accurate representation of renal function and response to therapeutic agents. The thickness of the renal tubule model and the composition of the cell layers are also defined in the patent claims to ensure consistency and reliability in the assessment of renal toxicity and transport molecule activity.
To know more about GlobalData’s detailed insights on Organovo, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
